Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

ReScript 12.0 has launched, marking a milestone in modernizing the language with a rewritten build system, improved ...

A fan of Lopatin’s early ambient releases, Josh Safdie contacted him while working out the sonic and emotional landscape of ...